CD4 and cancer: In other words, SLC35A2 is involved in tumor immune evasion and cancer progression by downregulating the number of activated tumor-infiltrating lymphocytes, such as CD8+ T cells, CD4+ T cells, NK cells, and B cells, and ultimately affecting patient survival.